PsilodexMedication × psilocybin
Your list , 0 items
Medication class

Antibiotics and psilocybin.

23 records in this group. None has published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.

23Records
0With human data

Also searched as antibiotic

01 What the evidence covers

Best evidence available per medication
23No psilocybin data
No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Each medication

A to Z
  • Amoxicillin · AmoxilEvidence: No psilocybin data

    Ear, nose and throat infections; Urinary and genital tract infections

    Not studied with psilocybin; no linking mechanism is described.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Amoxicillin–clavulanate · AugmentinEvidence: No psilocybin data

    Lower respiratory tract infections; Ear infections (otitis media)

    Not studied with psilocybin; no linking mechanism is described. Also, its label warns of liver problems.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Azithromycin · ZithromaxEvidence: No psilocybin data

    Respiratory infections (bacterial COPD flare-ups, sinusitis, pneumonia); Strep throat and tonsillitis

    Any interaction with psilocybin is theoretical. Also, it can affect heart rhythm, more so alongside other drugs with that effect.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Cefdinir · OmnicefEvidence: No psilocybin data

    Community-acquired pneumonia; Bronchitis flare-ups (acute exacerbations of chronic bronchitis)

    Not studied with psilocybin; no linking mechanism is described.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • CefuroximeEvidence: No psilocybin data

    Pharyngitis/tonsillitis; Acute bacterial otitis media

    Not studied with psilocybin; no linking mechanism is described.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Cephalexin · KeflexEvidence: No psilocybin data

    Respiratory tract infections; Middle ear infection (otitis media)

    Not studied with psilocybin; no linking mechanism is described.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Ciprofloxacin · CiproEvidence: No psilocybin data

    Skin infections; Bone and joint infections

    Not studied with psilocybin; its rare hallucinations and psychotic reactions can overlap psilocybin's effects. Also, it can affect heart rhythm and raise seizure risk.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • ClarithromycinEvidence: No psilocybin data

    Respiratory tract infections (bronchitis flares, sinusitis, community-acquired pneumonia, strep throat); Uncomplicated skin infections

    It may slow how the body clears psilocybin by blocking an enzyme. Also, it can affect heart rhythm, and its label lists liver injury.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Clindamycin · CleocinEvidence: No psilocybin data

    Serious respiratory tract infections; Serious skin and soft tissue infections

    Not studied with psilocybin; no linking mechanism is described.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Doxycycline · VibramycinEvidence: No psilocybin data

    Rickettsial infections (e.g., Rocky Mountain spotted fever); Sexually transmitted infections (e.g., chlamydia, gonorrhea, syphilis)

    Not studied with psilocybin; no linking mechanism is described.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Erythromycin · Ery-Tab, Erythrocin, PCE, E.E.S.Evidence: No psilocybin data

    Respiratory tract infections (including Legionnaires' disease); Skin and soft tissue infections

    It may somewhat slow how the body clears psilocybin. Also, it can cause heart-rhythm (QT) effects, more so with similar drugs.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • IsoniazidEvidence: No psilocybin data

    Tuberculosis (all forms, with other antituberculosis drugs); Preventive therapy for tuberculosis infection in higher-risk groups

    Its label reports some MAO (an enzyme) inhibiting activity, so it may alter how the body clears psilocybin. Also, it can cause severe hepatitis.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Levofloxacin · LevaquinEvidence: No psilocybin data

    Pneumonia (hospital- and community-acquired); Skin and skin structure infections

    Not studied with psilocybin. Also, it can cause psychosis or hallucinations from the first dose and affects heart rhythm, seizure threshold and blood sugar.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Linezolid · ZyvoxEvidence: No psilocybin data

    Pneumonia (hospital- and community-acquired); Skin and skin structure infections (including diabetic foot infections)

    It weakly blocks MAO (an enzyme), so it may alter how the body clears psilocybin; its label warns of serotonin syndrome with serotonin-boosting drugs.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Metronidazole · FlagylEvidence: No psilocybin data

    Trichomoniasis; Amebiasis (intestinal and liver abscess)

    Not studied with psilocybin; no linking mechanism is described. Also, its label reports seizures and nerve effects.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Moxifloxacin · AveloxEvidence: No psilocybin data

    Community-acquired pneumonia; Skin and skin structure infections

    Not studied with psilocybin; its boxed warning covers seizures, anxiety, confusion, hallucinations and paranoia. Also, it can change heart rhythm.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Nitrofurantoin · MacrobidEvidence: No psilocybin data

    Uncomplicated bladder infection (acute cystitis) from susceptible bacteria

    Not studied with psilocybin; no linking mechanism is described. Also, it is a common cause of drug-related liver disease.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Ofloxacin · OcufloxEvidence: No psilocybin data

    Bacterial conjunctivitis (pink eye); Bacterial corneal ulcers

    Not studied with psilocybin; these eye drops barely reach the body. Also, oral drugs in this class can change heart rhythm.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Penicillin VEvidence: No psilocybin data

    Mild to moderate streptococcal infections (including strep throat, scarlet fever); Mild to moderate pneumococcal respiratory infections

    Not studied with psilocybin; no linking mechanism is described.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • RifabutinEvidence: No psilocybin data

    Prevention of disseminated Mycobacterium avium complex (MAC) disease in advanced HIV infection

    Not studied with psilocybin; it speeds an enzyme with a minor role in clearing psilocybin, so slightly weaker effects are possible.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Rifampin · RifadinEvidence: No psilocybin data

    Tuberculosis (all forms, with other drugs); Meningococcal carriers without symptoms (to eliminate Neisseria meningitidis from the nasopharynx)

    Not studied with psilocybin; it speeds the enzymes that clear psilocybin, so weaker or shorter effects are possible. Also, its label warns of liver injury.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Sulfamethoxazole–trimethoprim · BactrimEvidence: No psilocybin data

    Urinary tract infections; Middle ear infection (acute otitis media) in children

    Not studied with psilocybin; no linking mechanism is described. Also, it rarely lowers blood sugar, and hallucinations are a listed side effect.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Tinidazole · TindamaxEvidence: No psilocybin data

    Trichomoniasis; Giardiasis

    Not studied with psilocybin. Also, its label reports seizures and a reaction with alcohol up to 3 days after the last dose.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

03 Properties the records flag

Records with each flag
8Liver injury
6Lowers seizure threshold or carries seizure risk
6QT-prolonging
5Hypoglycemia risk
4Psychiatric reactions
2MAO inhibition
2Speeds up drug metabolism
1Raises blood pressure or heart rate
1Serotonergic

Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.

04 State rules

Official text governs
COColorado · final · checked 2026-10-24

No provision names these medications or this group.

OROregon · final · checked 2026-10-24

No provision names these medications or this group.

NMNew Mexico · pending · checked 2026-10-24

Rules not final; the proposed rules reviewed name no medication in this group.

05 Studies cited in this group

Records citing each
15Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
15Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.
6Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689.
2Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303.
2Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 1996;73:229–233.
2Chen J, Wang Z, Yong CY, et al. Elucidating the Phase I metabolism of psilocin in vitro. Arch Toxicol 2025;99(3):1085–1094.
2Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025.
1Vojtěchovský M, Hort V, Šafratová V. Influence of MAO inhibitors on psilocybine induced psychosis. Activitas Nervosa Superior 1968;10(3):278–279 (via Tap 2025).

Related classes

Records reviewed 2026-09-30 to 2026-10-14. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z

AgreementPsilodex

Before you use Psilodex

Check each box to continue.

Your searches, your list and the medications you look up stay in this browser. We can't see them. Privacy · Emergency: 911 · Mental health crisis: call or text 988 · Poison Control: 1-800-222-1222

Terms version 2026-10-25